Tigatuzumab

Names

[ Name ]:
Tigatuzumab

Biological Activity

[Description]:

Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell Apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer[1].

[Related Catalog]:

Signaling Pathways >> Apoptosis >> Apoptosis

Research Areas >> Cancer

[In Vitro]

Tigatuzumab is sensitive to MIA PaCa-2 cells and BxPC-3 cells with IC50 values of 2.95 and 8.21 μg/mL, respectively[1]. Tigatuzumab (3-8 μg/mL; 5 h) induces apoptosis of cancer cells[1]. Apoptosis Analysis[1] Cell Line: MIA PaCa-2 and BxPC-3 cell lines Concentration: 3 and 8 μg/mL Incubation Time: 5 hours Result: Induced cell apoptosis, and the methionine restriction increased the caspase activation and apoptosis in pancreatic cancer cells.

[In Vivo]

Tigatuzumab (3 mg/kg; i.v. weekly for 4 weeks) effectively represses the tumor growth in human pancreatic cancer MIA PaCa-2-RFP orthotopic mouse model[1]. Animal Model: Nude mice with MIA PaCa-2-RFP human pancreatic cancer cells injection[1] Dosage: 3 mg/kg Administration: Intravenous injection; 3 mg/kg weekly for 4 weeks Result: Reduced the tumor volume and decreased the density of viable cancer cells in tumors.

[References]

[1]. Yamamoto J, et al. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model. Cancer Lett. 2020 Nov 1;492:174-184.

Chemical & Physical Properties

[ Molecular Weight ]:
144.6 (kDa)

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.